Navigation Links
Endo Pharmaceuticals Reports Strong Fourth Quarter and Full-Year 2009 Financial Results: Provides 2010 Financial Guidance
Date:2/22/2010

sition-related items (93,081) 93,081 (5) - Operating income 390,024 129,766 519,790 Interest (income) expense, net 37,718 (14,719) (6) 22,999 Other (income) expense, net (3,329) 3,560 (7) 231 Gain on extinguishment of debt (4,025) 4,025 (8) - Income before income taxes 359,660 136,900 496,560 Income taxes 93,324 68,948 (9) 162,272 Net income $266,336 $67,952 $334,288 Diluted earnings per share $2.27 $2.84 Diluted weighted average shares 117,515 117,515 Notes to reconciliation of our GAAP statements of operations to our adjusted statements of operations: (1) To exclude amortization of commercial intangible assets related to marketed products of $62,931 and the impact of an Indevus inventory step-up recorded as part of acquisition accounting of $11,268. (2) To exclude certain separation payments. (3) To exclude upfront and milestone payments to partners. (4) To exclude the impairment of AVEED and PRO2000 for $65,000 and $4,000, respectively. (5) To exclude Indevus transaction and separation costs of $35,009 as well as the impact, under purchase accounting, of a gain recorded to reflect the change in the company's current estimate of fair value, in accordance with GAAP, of the contingent consideration associated with the Indevus acquisition of ($128,090). (6) To exclude additional interest expense as a result of adopting ASC 470-20 of $15,781 and to exclude the amortization of the premium on debt acquire
'/>"/>
SOURCE Endo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014   Mast ... biopharmaceutical company, announced today that Santosh Vetticaden, Chief ... leaving the Company, for personal reasons, in mid-September.  ... Medical Officer of Aires Pharmaceuticals, which Mast acquired ... responsibilities as the Company,s interim Chief Medical Officer.  ...
(Date:8/29/2014)... , Aug. 29, 2014 Research and ... "China Orthopedic Instrument Industry Report, 2014-2017" report to ... population and rising proportion of reimbursement for medical expenses, ... released, with its scale presenting a CAGR of 19.2% ... are three product segments of orthopedic instruments in ...
(Date:8/29/2014)... -- Does your doctor know what you,re smoking?  Chances are, ... to the over 112,000 currently registered patients under ... other roughly 20,300+ active physicians listed with the Colorado Dept ... even though a poll in February 2014 showed 51% of ... it. "With marijuana legalization underway, every doctor ...
Breaking Medicine Technology:Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4China Orthopedic Instrument Industry Report, 2014-2017 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 3Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 4
... , HOFFMAN ESTATES, Ill., Sept. 30 Life Spine ... (FDA) has given 510(k) marketing approval to the SENTINEL ... provides rigid stabilization and promotes fusion from the occiput ... to address complicated procedures. Polyaxial screws are available in ...
... JERUSALEM, Israel, September 30 ... carlecortemcel-l, the generic,name of what is widely known as ... and lymphoma. The article, carlecortemcel-l, an ex vivo expanded,umbilical ... Ka Wah Chan and Dr. Demetrios Petropoulos, will be ...
Cached Medicine Technology:Article Published in Expert Opinion on Biological Therapy Evaluates StemEx(R) (carlecortemcel-l) for Leukemia and Lymphoma 2Article Published in Expert Opinion on Biological Therapy Evaluates StemEx(R) (carlecortemcel-l) for Leukemia and Lymphoma 3
(Date:9/1/2014)... Steven Reinberg HealthDay Reporter ... a head-to-head comparison, an experimental drug was more effective ... heart failure patients. According to the study authors, ... benefit of the new drug, dubbed LCZ696. ... standard medication, enalapril (Vasotec), either died or were hospitalized ...
(Date:9/1/2014)... Watching action shows on TV may be bad for your ... snack food while watching action films and programs than something ... find that if you,re watching an action movie while snacking ... Tal, of the Cornell Food and Brand Lab, said in ... the program is, the more you will eat." The ...
(Date:9/1/2014)... September 01, 2014 Currently, scientists ... effective treatments for Alzheimer's disease (AD), which reflects ... exist regarding the diagnosis of the disease, especially ... of appropriate diagnostic tests. In 2014, after ... greatest breakthroughs in the medicine world, there are ...
(Date:9/1/2014)... York, NY (PRWEB) September 01, 2014 ... have been added to a federal litigation that continues ... South Carolina, Bernstein Liebhard LLP reports. , A ... claims now filed over the widely-used cholesterol medication by ... the drug. According to claims, Pfizer Inc. failed to ...
(Date:9/1/2014)... 2014 The B-cell non-Hodgkin’s Lymphoma (NHL) ... major markets (the US, France, Italy, Germany, Spain and ... billion by 2018. , The competitive landscape in the ... Spain and the UK is poised to undergo a ... the four largest B-cell NHL indications, which includes Diffuse ...
Breaking Medicine News(10 mins):Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 2Health News:Drug Gives 'New Hope' Against Heart Failure, Expert Says 3Health News:Action-Packed TV a Threat to Your Waistline? 2Health News:Early Stage Minimally Invasive Candidate AD Biomarkers Reviewed in New Study by Biopharm Reports Available at MarketPublishers.com 2Health News:Early Stage Minimally Invasive Candidate AD Biomarkers Reviewed in New Study by Biopharm Reports Available at MarketPublishers.com 3Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 2Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 2Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 4
... patients who do not respond to traditional therapy can ... transplant, according to an Indiana University School of Medicine ... England Journal of Medicine. , About 90 percent ... involves multiple courses of cisplatin, first used successfully in ...
... are urgently needed to reduce climate-altering carbon emissions that ... the World Health Organisation said Monday. ,Climate change ... in the region, according to WHO estimates. ,"So ... If the trend continues, it may have an impact on ...
... for tougher regulations on tobacco, as officials from 145 ... global efforts to stop smoking. ,The ... aims to find ways of harmonising national laws to ... from second-hand smoke. ,Hatai Chitanondh, the president ...
... who have difficulty recognizing familiar smells could be experiencing an ... Monday. ,Scientists already know that the first ... in an area of the brain that is home to ... Center in Chicago tested 589 people aged between 54 to ...
... Idaho in US had a miraculous escape while traveling by an ... the pilot last Wednesday from Twin Falls, Idaho, to Seattle when ... at a height of 20,000 ft. ,Rapid decompression occurred ... water bottle. Fogg's head and right arm were pulled outside the ...
... New York based Columbia University Medical Center has shown that ... form of alcohol use disorder at some point in ... the adults surveyed reported experiencing alcohol abuse, and 12.5 per ... an article published in the Archives of General Psychiatry, one ...
Cached Medicine News:Health News:Advanced therapy offers cure for relapsed cancer patient 2Health News:UN Calls for Pedal Power to Reduce Environmental Damage 2Health News:Tougher Tobacco Rules Urged at Global Anti-smoking Talks 2Health News:Nurse Has Miraculous Escape as Window is Blown Off an Air Ambulance 2Health News:One-third of Adults Have Had Some Form of Alcohol Use Disorder During Their Lifetimes 2
... medication nebulizer achieves optimum lung penetration for ... range is 1.04-1.10 µ at 6-8 LPM. ... outlet., ,As the world leader in ... the assurance of proven technology by offering ...
... dose inhalers., ,ACE ensures prompt, effective ... Its versatile design allows it to be ... with an endotracheal airway or resuscitation bag ... also be used in conjunction with an ...
... as well as humidification, try Flo-Mist™., ... volume, continuous medication nebulizer (CMN), engineered to ... 200 ml reservoir and jet flow design ... nebulized medication delivery at 25 ml/hr. Particles ...
... Nebulizer Small Volume Medication Mouthpiece 7FT O 2 ... ,An advanced jet design for fast treatment times ... with a tighter distribution (higher percentage of respirable ... ,Our AirLife™ brand Misty Max 10™ disposable nebulizers ...
Medicine Products: